Mutant Lung News Today

Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU data Submission to be reviewed under FDA Real Time Oncology Review and Project Orbis If approved,...

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumours who have ...

Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population Results reaffirm...

AstraZeneca and Daiichi Sankyo’s ENHERTU showed objective response rates of 49% and 56% with 5.4mg/kg and 6.4mg/kg doses respectively in primary analysis ENHERTU provided a median...

Designations for Daiichi Sankyo and AstraZenecas ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colorectal cancer ENHERTU has now been granted...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Jul 27, 2023--

Data support ongoing discussions with global health authorities ...

The treatment combination of Rybrevant and chemotherapy significantly improved progression-free survival rates for patients newly diagnosed with metastatic NSCLC with EGFR Exon 20 insertion mutations.

AstraZeneca and Daiichi Sankyo’s ENHERTU showed an objective response rate of 37.1% in the overall population of the DESTINY-PanTumor02 Phase II trial ENHERTU is the first therapy to show... | June 5, 2023

The phase 3 HARMONi trial recently kicked off, studying ivonescimab plus chemotherapy for EGFR-mutant non-small cell lung cancer.